ROS アッセイ評価報告書 - jacvam.jp

評価会議報告書 - JaCVAM

1 . 評価会議報告書. human Cell Line Activation Test （h-CLAT） JaCVAM. 評価会議. 平成. 28 年（2016 年）12 月20 日

  Tacl, H clat

皮膚感作性試験評価報告書 - JaCVAM

1 . 皮膚感作性試験評価報告書. human Cell Line Activation Test （hCLAT 平成. 28 年12 月20 日. JaCVAM. 皮膚感作性試験資料編纂委員会

  Tests

動物実験代替法の現状と今後の展開 - JaCVAM

1－10 10－100 100－1000 1000以上 8.1 皮膚刺激性または皮膚腐食性(in vitro) 8.1.1 皮膚刺激性(in vivo) 8.2 眼刺激性（in vitro） 8.2.1 眼刺激性（in vivo） 8.3 皮膚感作性 8.4 遺伝毒性

Thomas Sudhop, MD - AGAH

1 What is required for first into man? The EU IMPD Thomas Sudhop, MD 2 Scope Structure and content of an IMPD What is required for first into man trial?

  Thomas, Thomas sudhop, Sudhop

Non-clinical Assessment Requirements

Non-clinical Assessment Requirements. Pharmacology • Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3[R2]) Dec 2009

  Assessment, Requirements, Clinical, Non clinical assessment requirements

S9 Step 5 Nonclinical evaluation for anticancer ...

This guideline aims to facilitate and accelerate the development of anticancer pharmaceuticals and to protect patients from unnecessary adverse effects, while avoiding unnecessary use of animals, in